Ophthalmology · GlaucomaRegulatory Approvalregulatorymid-term

FDA Grants Approval for Brimonidine Tartrate ANDA220398 by Mankind Pharma

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Mankind Pharma2 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/4/2026, 6:31:31 PM

Assessment confidence: 43% · The main uncertainty is whether medium-relevance evidence fully captures sub-indication-specific dynamics.

Executive Thesis

The FDA's approval of Mankind Pharma's ANDA for Brimonidine Tartrate signifies a new competitor entering the glaucoma treatment market, which could disrupt existing pricing and market share dynamics. Portfolio teams must evaluate the implications for their current products and strategies in light of this increased competition. Regulatory context from FDA (FDA AP — BRIMONIDINE TARTRATE (ORIG)) supports the near-term read. Assessment grounded in 9 ranked evidence items (0 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this new entrant on market dynamics and pricing strategies for existing products. The strongest clinical anchor is Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment (ClinicalTrials.gov), weak alignment to signal sub-indication and entities. In ophthalmology, 8 regulatory and 1 competitive items passed relevance filtering for Mankind Pharma.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). This approval allows Mankind Pharma to enter the market for Brimonidine Tartrate, potentially increasing competition in the glaucoma treatment space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — BRIMONIDINE TARTRATE (ORIG) (FDA). Entity match (mankind pharma); Regulatory pathway relevance (nda).

Key Risks

Elevated medium regulatory exposure for Mankind Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of Mankind Pharma could lead to price pressures and shifts in market share among existing players, impacting revenue projections for current glaucoma treatments.
Portfolio teams should assess the impact of this new entrant on market dynamics and pricing strategies for existing products.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and any subsequent competitive responses from established players in the glaucoma market.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — BRIMONIDINE TARTRATE (ORIG)
FDAmedium relevance
Entity match (mankind pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (ORIG)
FDAmedium relevance
Entity match (mankind pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE AND TIMOLOL MALEATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (ORIG)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BRIMONIDINE TARTRATE (SUPPL)
FDAmedium relevance
Entity match (brimonidine tartrate); Regulatory pathway relevance (nda)
FDA document
View source

Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)
FDA to Terminate Emergency Use Authorizations for COVID-19 Drugs
Humanexa Signalslow relevance
Weak alignment to signal sub-indication and entities

Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Insect-based models in pharmaceutical ecotoxicology: a bibliometric and narrative review.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Wedelactone-loaded exosomes for sepsis-induced liver injury: a novel therapeutic strategy.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Mankind Pharma
Brimonidine Tartrate
glaucoma treatment market

Commercial impact

medium

The entry of Mankind Pharma could lead to price pressures and shifts in market share among existing players, impacting revenue projections for current glaucoma treatments.

Regulatory impact

medium

This approval indicates a successful regulatory pathway for Mankind Pharma, which may encourage similar applications from other companies, potentially altering the regulatory landscape for glaucoma treatments.

What to watch

Monitor market entry timelines and any subsequent competitive responses from established players in the glaucoma market.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.